Baker McKenzie authorized advisor to X Shore in main placement of roughly SEK 300 million | Newsroom Advisor
Baker McKenzie authorized advisor to the Joint Bookrunners in Cibus’ main issuance of shares of SEK 810 million | Newsroom Advisor
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Major Endpoint of Development-Free Survival (PFS) as First-Line Remedy for Superior or Recurrent Endometrial Carcinoma Articles